In September 2002, Zhejiang Wolwo Bio-pharmaceutical Co.,Ltd was founded and started the journey dedicated to the R&D, production and sales of products for allergic disease diagnosis and treatment.
In October 2006, the dust mite desensitization treatment product independently developed by the Company, "Dermatophagoides Farinae Drops" (trade name: "Chanllergen"), obtained the drug GMP certificate issued by CFDA, and officially went on sale.
According to the "2008-2012 National Allergic Disease Drug Market Inquiry Report" by CFDA Southern Institute, the Company’s main product
"Chanllergen" has occupied the largest market share.
With the development of the company and the enlarging product portfolio, Wolwo went public on the Growth Enterprise Market in 2014, with the stock code "Wolwo Biotech" and the stock code "300357".
In 2016, the Company's products officially entered South Korea market, taking the first step onto the international arena